Authors : Neha Bagga, Preeti Agarwal, Rajat Kumar Tuteja, Raj Mehrotra, Kul Ranjan Singh
DOI : 10.18231/j.ijpo.2021.022
Volume : 8
Issue : 1
Year : 2021
Page No : 111-119
Background: Triple negative breast cancers (TNBC), a pathologically high grade subset of tumours has increasing prevalence in Indian population. Since their morphological features resemble with BRCA1 mutated inherited breast cancer, the present study was aimed to define the role of BRCA1 mutation in sporadic breast cancer.
Aims and Objectives: 1. To evaluate immunohistochemical expression of BRCA-1 in non familial breast cancer cases and to correlate with clinical and histopathological parameters.
Setting and Design: Prospective & Retrospective study (August 2014-August 2015). Tertiary care hospital in North Eastern India
Materials and Methods: 189 cases of suspected breast cancer cases were included in the study. ER/PR/HER2 status was evaluated of 114 cases and molecular classification along with BRCA1 expression was seen in 62 patients.
Statistical analysis: SPSS (Statistical Package for Social Sciences) Version 15.0 statistical Analysis Software. The values were represented in Number (%) and Mean±SD.
Result: 71.56% of cases belonged to Nottingham’s grade II and III. Among our groups maximum percentage were of TNBC (basal + non basal) and Her2 enriched i.e (30.6% respectively) followed by luminal B (24.2%) and luminal A (9.6%). 50% of cases in study sub population showed BRCA 1 loss.
BRCA1 expression was nuclear and cytoplasmic in both control and cases. Maximum mean BRCA1 loss was seen in basal like, followed by triple negative non basal like, her2 enriched and minimum in luminal A.
Conclusion: Large percentage of TNBC, increased BRCA1 expression loss and high grade, indicates need to fulfil the vacant space of therapeutic modality in TNBC management. PARP inhibitors, the future of therapeutic management of TNBC might also be helpful in sporadic cases of breast cancer exhibiting BRCA1 expression loss.
Keywords: BRCA1, Breast cancer, Triple negative breast cancers (TNBC).